TRDA

4.3506.25%
DD

Dipal Doshi

CEO & Director

Mr. Dipal Doshi is Independent Director of Azenta, Inc. from January 30, 2025. Mr. Doshi serves as Director of The Children's Health Fund. He serves as Director of Ashibio, Inc since September 2024. Mr. Doshi has been Chief Executive Officer and Director of Entrada Therapeutics, Inc. since August 2017 and served as President since August 2017. He served as the Chief Business Officer at Amicus Therapeutics, Inc. since September 21, 2015 until August 9, 2017. Mr. Doshi served as General Manager of Scioderm, Inc. until August 9, 2017. Mr. Doshi founded RStreet Advisors. Mr. Doshi served as Senior Vice President of Strategy & Business Development at Amicus Therapeutics, Inc. since July 2014 until September 21, 2015. Mr. Doshi served as Senior Vice President of Business Planning & Development at Amicus Therapeutics, Inc. since July 2014. Mr. Doshi served as the Vice President of Investments & Business Development at Auven Therapeutics Management L.L.L.P. Mr. Doshi joined Celtic Therapeutics Holdings in 2008 and served as Vice President on the Investment Team. He served as the Head of Corporate Development for Catalent Pharma Solutions, Inc. Mr. Doshi was a member of Merrill Lynch's Investment Banking Group where he advised private equity and hedge fund clients on a variety of portfolio, growth and financing issues. During his tenure at Eli Lilly & Company, he led an internal portfolio company sponsored by Lilly Ventures and also served as a sales representative in New York. Mr. Doshi worked for Mercer Management Consulting and Sapient Corporation advising healthcare, consumer and technology companies on their strategic and operational issues. He holds an M.B.A. from The Wharton School and a B.A. from Rutgers College, Rutgers University. Mr. Doshi is a Fellow of the Aspen Institute.

公司職務